Login Register Cart 0
Generic placeholder image

Current Drug Discovery Technologies

Editor-in-Chief

ISSN (Print): 1570-1638
ISSN (Online): 1875-6220

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Mini-Review Article

Fatty Acid Biosynthesis: An Updated Review on KAS Inhibitors

Author(s): Rani Shinde and Vasanti Suvarna*

Volume 19, Issue 2, 2022

Published on: 14 February, 2022

Article ID: e110122200137 Pages: 15

DOI: 10.2174/1570163819666220111113032

Price: $65

Abstract

Since the early twentieth century, with the isolation of penicillin and streptomycin in the 1940s, the modern era of anti-infective drug development has gained momentum. Due to the enormous success of early drug discovery, many infectious diseases were successfully prevented and eradicated. However, this initial hope was wrongheaded, and pathogens evolved as a significant threat to human health. Drug resistance develops as a result of natural selection’s relentless pressure, necessitating the identification of new drug targets and the creation of chemotherapeutics that bypass existing drug resistance mechanisms. Fatty acid biosynthesis (FAS) is a crucial metabolic mechanism for bacteria during their growth and development. Several crucial enzymes involved in this biosynthetic pathway have been identified as potential targets for new antibacterial agents. In Escherichia coli (E. coli), this pathway has been extensively investigated. The present review focuses on progress in the development of Kas A, Kas B, and Fab H inhibitors as mono-therapeutic antibiotics.

Keywords: Fatty acid biosynthesis, Kas A, Kas B, FabH, bacterium, acyl carrier protein, condensing enzyme.

Graphical Abstract

[1]
Song X, Yang Y, Zhao J, Chen Y. Synthesis and antibacterial activity of cinnamaldehyde acylhydrazone with a 1,4-benzodioxan fragment as a novel class of potent β-ketoacyl-acyl carrier protein synthase III (FabH) inhibitor. Chem Pharm Bull (Tokyo) 2014; 62(11): 1110-8.
[http://dx.doi.org/10.1248/cpb.c14-00485] [PMID: 25196128]
[2]
Wang J, Soisson SM, Young K, et al. Platensimycin is a selective FabF inhibitor with potent antibiotic properties. Nature 2006; 441(7091): 358-61.
[http://dx.doi.org/10.1038/nature04784] [PMID: 16710421]
[3]
Available from: https://www.nature.com/articles/431892a.pdf
[4]
Musayev F, Sachdeva S, Scarsdale JN, Reynolds KA, Wright HT. Crystal structure of a substrate complex of Mycobacterium tuberculosis β-ketoacyl-acyl carrier protein synthase III (FabH) with lauroyl-coenzyme A. J Mol Biol 2005; 346(5): 1313-21.
[http://dx.doi.org/10.1016/j.jmb.2004.12.044] [PMID: 15713483]
[5]
Wright HT, Reynolds KA. Antibacterial targets in fatty acid biosynthesis. Curr Opin Microbiol 2007; 10(5): 447-53.
[http://dx.doi.org/10.1016/j.mib.2007.07.001] [PMID: 17707686]
[6]
Price AC, Choi KH, Heath RJ, Li Z, White SW, Rock CO. Inhibition of β-ketoacyl-acyl carrier protein synthases by thiolactomycin and cerulenin. Structure and mechanism. J Biol Chem 2001; 276(9): 6551-9.
[http://dx.doi.org/10.1074/jbc.M007101200] [PMID: 11050088]
[7]
Casillas-Vargas G, Ocasio-Malavé C, Medina S, et al. Antibacterial fatty acids: An update of possible mechanisms of action and implications in the development of the next-generation of antibacterial agents. Prog Lipid Res 2020; 2021: 82.
[PMID: 33577909]
[8]
Sanyal R, Singh V, Harinarayanan R. A novel gene contributing to the initiation of fatty acid biosynthesis in Escherichia coli. J Bacteriol 2019; 201(19): e00354-19.
[http://dx.doi.org/10.1128/JB.00354-19] [PMID: 31331975]
[9]
Campbell JW, Cronan JE Jr. Bacterial fatty acid biosynthesis: targets for antibacterial drug discovery. Annu Rev Microbiol 2001; 55: 305-32. Available from: http://www.annualreviews.org/doi/ 10.1146/annurev.micro.55.1.305
[http://dx.doi.org/10.1146/annurev.micro.55.1.305] [PMID: 11544358]
[10]
Ekström AG, Kelly V, Marles-Wright J, Cockroft SL, Campopiano DJ. Structural evidence for the covalent modification of FabH by 4,5-dichloro-1,2-dithiol-3-one (HR45). Org Biomol Chem 2017; 15(30): 6310-3.
[http://dx.doi.org/10.1039/C7OB01396E] [PMID: 28715001]
[11]
Tsay J-T, Rock C. Overproduction of 3-ketoacyl-acyl carrier protein synthase I imparts thiolactomycin resistance to Escherichia coli K-12. J Bacteriol 1992; 174(2): 508-13.
[http://dx.doi.org/10.1128/jb.174.2.508-513.1992]
[12]
Li HX, Wang ZC, Qian YM, Yan XQ, Lu YD, Zhu HL. Design, synthesis, and biological evaluation of chrysin derivatives as potential FabH inhibitors. Chem Biol Drug Des 2017; 89(1): 136-40.
[http://dx.doi.org/10.1111/cbdd.12839] [PMID: 27860280]
[13]
White SW, Zheng J, Zhang YM, Rock CO. The structural biology of type II fatty acid biosynthesis. Annu Rev Biochem 2005; 74: 791-831.
[http://dx.doi.org/10.1146/annurev.biochem.74.082803.133524] [PMID: 15952903]
[14]
Ramamoorthy D, Turos E, Guida WC. Identification of a new binding site in E. coli FabH using Molecular dynamics simulations: validation by computational alanine mutagenesis and docking studies. J Chem Inf Model 2013; 53(5): 1138-56.
[http://dx.doi.org/10.1021/ci3003528] [PMID: 23581389]
[15]
Nie Z, Perretta C, Lu J, et al. Structure-based design, synthesis, and study of potent inhibitors of β-ketoacyl-acyl carrier protein synthase III as potential antimicrobial agents. J Med Chem 2005; 48(5): 1596-609. https://pubs.acs.org/doi/10.1021/jm049141s[Internet].
[http://dx.doi.org/10.1021/jm049141s] [PMID: 15743201]
[16]
Khandekar SS, Daines RA, Lonsdale JT. Bacterial β-ketoacyl-acyl carrier protein synthases as targets for antibacterial agents. Curr Protein Pept Sci 2003; 4(1): 21-9.
[http://dx.doi.org/10.2174/1389203033380377] [PMID: 12570782]
[17]
Song H, Ao GZ, Li HQ. Novel FabH inhibitors: An updated article literature review (July 2012 to June 2013). Expert Opin Ther Pat 2014; 24(1): 19-27.
[18]
Singh R, Mo S, Florova G, Reynolds KA. Streptomyces coelicolor RedP and FabH enzymes, initiating undecylprodiginine and fatty acid biosynthesis, exhibit distinct acyl-CoA and malonyl-acyl carrier protein substrate specificities. FEMS Microbiol Lett 2012; 328(1): 32-8.
[http://dx.doi.org/10.1111/j.1574-6968.2011.02474.x] [PMID: 22136753]
[19]
Qiu X, Choudhry AE, Janson CA, et al. Crystal structure and substrate specificity of the β-ketoacyl-acyl carrier protein synthase III (FabH) from Staphylococcus aureus. Protein Sci 2005; 14(8): 2087-94.
[http://dx.doi.org/10.1110/ps.051501605] [PMID: 15987898]
[20]
Lee JY, Lee E, Jeong KW, Kim Y. Antimicrobial flavonoid, 3,6-dihydroxyflavone, have dual inhibitory activity against KAS III and KAS i. Bull Korean Chem Soc 2011; 32(9): 3219-22.
[http://dx.doi.org/10.5012/bkcs.2011.32.9.3219]
[21]
Zhang D, Zhang F, Liu W. A KAS-III heterodimer in lipstatin biosynthesis nondecarboxylatively condenses C8 and C14 fatty acyl-coa substrates by a variable mechanism during the establishment of a C22 aliphatic skeleton. J Am Chem Soc 2019; 141(9): 3993-4001.
[http://dx.doi.org/10.1021/jacs.8b12843] [PMID: 30763089]
[22]
Volker C, Brown JR. Bioinformatics and the discovery of novel anti-microbial targets. Curr Drug Targets Infect Disord 2002; 2(4): 279-90.
[http://dx.doi.org/10.2174/1568005023342326] [PMID: 12570736]
[23]
Lee JY, Jeong KW, Lee JU, Kang DI, Kim Y. Novel E. coli β-ketoacyl-acyl carrier protein synthase III inhibitors as targeted antibiotics. Bioorg Med Chem 2009; 17(4): 1506-13.
[http://dx.doi.org/10.1016/j.bmc.2009.01.004] [PMID: 19185501]
[24]
Lv PC, Wang KR, Yang Y, et al. Design, synthesis and biological evaluation of novel thiazole derivatives as potent FabH inhibitors. Bioorg Med Chem Lett 2009; 19(23): 6750-4.
[http://dx.doi.org/10.1016/j.bmcl.2009.09.111] [PMID: 19836235]
[25]
Gerusz V. Recent Advances in the inhibition of bacterial fatty acid biosynthesis. Annu Reports Med Chem 2010; 45: 295-311.
[http://dx.doi.org/10.1016/S0065-7743(10)45018-6]
[26]
Li HQ, Luo Y, Lv PC, Shi L, Liu CH, Zhu HL. Design and synthesis of novel deoxybenzoin derivatives as FabH inhibitors and anti-inflammatory agents. Bioorg Med Chem Lett 2010; 20(6): 2025-8.
[http://dx.doi.org/10.1016/j.bmcl.2010.01.032] [PMID: 20153183]
[27]
Zhang HJ, Qin X, Liu K, Zhu DD, Wang XM, Zhu HL. Synthesis, antibacterial activities and molecular docking studies of Schiff bases derived from N-(2/4-benzaldehyde-amino) phenyl-N'-phenyl-thiourea. Bioorg Med Chem 2011; 19(18): 5708-15.
[http://dx.doi.org/10.1016/j.bmc.2011.06.077] [PMID: 21872479]
[28]
Zhou Y, Du QR, Sun J, et al. Novel Schiff-base-derived FabH inhibitors with dioxygenated rings as antibiotic agents. ChemMedChem 2013; 8(3): 433-41.
[http://dx.doi.org/10.1002/cmdc.201200587] [PMID: 23401291]
[29]
Li Y, Zhao CP, Ma HP, et al. Design, synthesis and antimicrobial activities evaluation of Schiff base derived from secnidazole derivatives as potential FabH inhibitors. Bioorg Med Chem 2013; 21(11): 3120-6.
[http://dx.doi.org/10.1016/j.bmc.2013.03.023] [PMID: 23602519]
[30]
Zhang X, Sangani CB, Jia LX, et al. Synthesis and antibacterial evaluation of novel Schiff’s base derivatives of nitroimidazole nuclei as potent E. coli FabH inhibitors. RSC Advances 2014; 4(97): 54217-25. [Internet].
[http://dx.doi.org/10.1039/C4RA08567A]
[31]
Zhang F, Wen Q, Wang SF, et al. Design, synthesis and antibacterial activities of 5-(pyrazin-2-yl)-4H-1,2,4-triazole-3-thiol derivatives containing Schiff base formation as FabH inhibitory. Bioorg Med Chem Lett 2014; 24(1): 90-5.
[http://dx.doi.org/10.1016/j.bmcl.2013.11.079] [PMID: 24332628]
[32]
Sangani CB, Makwana JA, Duan YT, et al. Design, synthesis, and antibacterial evaluation of new Schiff’s base derivatives bearing nitroimidazole and pyrazole nuclei as potent E. coli FabH inhibitors. Res Chem Intermed 2015; 41(12): 10137-49. [Internet].
[http://dx.doi.org/10.1007/s11164-015-2018-1]
[33]
Alam MS, Jebin S, Rahman MM, Bari L. Biological and quantitative-SAR evaluations, and docking studies of (E)-N-benzylidenebenzohydrazide analogues as potential antibacterial agents. EXCLI J 2016; 350-61.
[34]
Zhou Y, Yang YS, Song XD, Lu L, Zhu HL. Study of Schiff-base-derived with dioxygenated rings and nitrogen heterocycle as potential β-ketoacyl-acyl carrier protein synthase III (FabH) inhibitors. Chem Pharm Bull (Tokyo) 2017; 65(2): 178-85.
[http://dx.doi.org/10.1248/cpb.c16-00772] [PMID: 28154310]
[35]
Luo Y, Zhang LR, Hu Y, et al. Synthesis and antimicrobial activities of oximes derived from O-benzylhydroxylamine as FabH inhibitors. ChemMedChem 2012; 7(9): 1587-93.
[http://dx.doi.org/10.1002/cmdc.201200225] [PMID: 22811397]
[36]
Jebli N, Arfaoui Y, Van Hecke K, Cavalier JF, Touil S. Experimental and computational investigation of Z/E isomerism, X-ray crystal structure and molecular docking study of (2-(hydroxyimino)cyclohexyl)diphenylphosphine sulfide, a potential antibacterial agent. J Mol Struct 2021; 1229: 1-11.
[http://dx.doi.org/10.1016/j.molstruc.2020.129634]
[37]
Wang XL, Zhang YB, Tang JF, et al. Design, synthesis and antibacterial activities of vanillic acylhydrazone derivatives as potential β-ketoacyl-acyl carrier protein synthase III (FabH) inhibitors. Eur J Med Chem 2012; 57: 373-82. [Internet].
[http://dx.doi.org/10.1016/j.ejmech.2012.09.009] [PMID: 23124163]
[38]
Segretti ND, Serafim RAM, Segretti MCF, et al. New antibacterial agents: Hybrid bioisoster derivatives as potential E. coli FabH inhibitors. Bioorg Med Chem Lett 2016; 26(16): 3988-93.
[http://dx.doi.org/10.1016/j.bmcl.2016.06.089] [PMID: 27426865]
[39]
Zhang HJ, Zhu DD, Li ZL, Sun J, Zhu HL. Synthesis, molecular modeling and biological evaluation of β-ketoacyl-acyl carrier protein synthase III (FabH) as novel antibacterial agents. Bioorg Med Chem 2011; 19(15): 4513-9.
[http://dx.doi.org/10.1016/j.bmc.2011.06.021] [PMID: 21741250]
[40]
Li Y, Luo Y, Hu Y, et al. Design, synthesis and antimicrobial activities of nitroimidazole derivatives containing 1,3,4-oxadiazole scaffold as FabH inhibitors. Bioorg Med Chem 2012; 20(14): 4316-22.
[http://dx.doi.org/10.1016/j.bmc.2012.05.050] [PMID: 22710102]
[41]
Wang ZC, Duan YT, Qin YJ, et al. Potentiating 1-(2-hydroxypropyl)-2-styryl-5-nitroimidazole derivatives against antibacterial agents: design, synthesis and biology analysis. Eur J Med Chem 2013; 65: 456-63. [Internet].
[http://dx.doi.org/10.1016/j.ejmech.2013.05.004] [PMID: 23770447]
[42]
Duan YT, Wang ZC, Sang YL, et al. Design and synthesis of 2-styryl of 5-Nitroimidazole derivatives and antimicrobial activities as FabH inhibitors. Eur J Med Chem 2014; 76: 387-96. [Internet].
[http://dx.doi.org/10.1016/j.ejmech.2014.02.004] [PMID: 24594526]
[43]
Yang YS, Zhang F, Gao C, et al. Discovery and modification of sulfur-containing heterocyclic pyrazoline derivatives as potential novel class of β-ketoacyl-acyl carrier protein synthase III (FabH) inhibitors. Bioorg Med Chem Lett 2012; 22(14): 4619-24.
[http://dx.doi.org/10.1016/j.bmcl.2012.05.091] [PMID: 22721711]
[44]
Salian VV, Narayana B, Sarojini BK, Kumar MS, Sharath CK, Lobo AG. Tailor made biheterocyclic pyrazoline-thiazolidinones as effective inhibitors of Escherichia coli FabH: Design, synthesis and structural studies. J Mol Struct 2019; 1192: 91-104. [Internet].
[http://dx.doi.org/10.1016/j.molstruc.2019.04.105]
[45]
Liu Y, Zhong W, Li RJ, Li S. Synthesis of potent inhibitors of β-ketoacyl-acyl carrier protein synthase III as potential antimicrobial agents. Molecules 2012; 17(5): 4770-81.
[http://dx.doi.org/10.3390/molecules17054770] [PMID: 22534662]
[46]
Kremer L, Dover LG, Carrère S, et al. Mycolic acid biosynthesis and enzymic characterization of the β-ketoacyl-ACP synthase A-condensing enzyme from Mycobacterium tuberculosis. Biochem J 2002; 364(Pt 2): 423-30.
[http://dx.doi.org/10.1042/bj20011628] [PMID: 12023885]
[47]
Bhatt A, Kremer L, Dai AZ, Sacchettini JC, Jacobs WR Jr. Conditional depletion of KasA, a key enzyme of mycolic acid biosynthesis, leads to mycobacterial cell lysis. J Bacteriol 2005; 187(22): 7596-606.
[http://dx.doi.org/10.1128/JB.187.22.7596-7606.2005] [PMID: 16267284]
[48]
Slayden RA, Barry CE III. The role of KasA and KasB in the biosynthesis of meromycolic acids and isoniazid resistance in Mycobacterium tuberculosis. Tuberculosis (Edinb) 2002; 82(4-5): 149-60.https://linkinghub.elsevier.com/retrieve/pii/S1472979202903331 [Internet].
[http://dx.doi.org/10.1054/tube.2002.0333] [PMID: 12464486]
[49]
Lu X, Chen Y, You Q. 3D-QSAR, molecular docking studies, and binding mode prediction of thiolactomycin analogs as mtFabH inhibitors. J Enzyme Inhib Med Chem 2010; 25(2): 240-9.
[http://dx.doi.org/10.3109/14756360903049059] [PMID: 19968566]
[50]
Machutta CA, Bommineni GR, Luckner SR, et al. Slow onset inhibition of bacterial β-ketoacyl-acyl carrier protein synthases by thiolactomycin. J Biol Chem 2010; 285(9): 6161-9.
[http://dx.doi.org/10.1074/jbc.M109.077909] [PMID: 20018879]
[51]
Paneerselvam V, Razack SA, Vaidyanathan G, Krishnasami I, Duraiarasan S. Isolation of thiolactomycin from soil actinomycetes and detection of its antibacterial effect against Mycobacterium tuberculosis. 2011; 4(12): 4618-20.
[52]
Schaefer B, Kisker C, Sotriffer CA. Molecular dynamics of Mycobacterium tuberculosis KasA: implications for inhibitor and substrate binding and consequences for drug design. J Comput Aided Mol Des 2011; 25(11): 1053-69.
[http://dx.doi.org/10.1007/s10822-011-9483-4] [PMID: 22076471]
[53]
Luo Y, Yang YS, Fu J, Zhu HL. Novel FabH inhibitors: A patent and article literature review (2000 2012). Expert Opin Ther Pat 2012; 22(11): 1325-36.
[54]
Schiebel J, Kapilashrami K, Fekete A, et al. Structural basis for the recognition of mycolic acid precursors by KasA, a condensing enzyme and drug target from Mycobacterium tuberculosis. J Biol Chem 2013; 288(47): 34190-204.
[http://dx.doi.org/10.1074/jbc.M113.511436] [PMID: 24108128]
[55]
Kapilashrami K, Bommineni GR, Machutta CA, et al. Thiolactomycin-based β-ketoacyl-AcpM synthase A (KasA) inhibitors: fragment-based inhibitor discovery using transient one-dimensional nuclear overhauser effect NMR spectroscopy. J Biol Chem 2013; 288(9): 6045-52.
[http://dx.doi.org/10.1074/jbc.M112.414516] [PMID: 23306195]
[56]
Bommineni GR, Kapilashrami K, Cummings JE, et al. Thiolactomycin-based inhibitors of bacterial β-ketoacyl-ACP synthases with in vivo activity. J Med Chem 2016; 59(11): 5377-90.
[http://dx.doi.org/10.1021/acs.jmedchem.6b00236] [PMID: 27187871]
[57]
Sager AA, Abood ZS, El-Amary WM, et al. Design, synthesis and biological evaluation of some triazole schiff’s base derivatives as potential antitubercular agents. Open Med Chem J 2018; 12(1): 48-59.
[http://dx.doi.org/10.2174/1874104501812010048] [PMID: 29854013]
[58]
Durairaj DR, Shanmughavel P. In silico drug design of thiolactomycin derivatives against mtb-kasa enzyme to inhibit multidrug resistance of mycobacterium tuberculosis. Interdiscip Sci 2019; 11(2): 215-25.
[http://dx.doi.org/10.1007/s12539-017-0257-0] [PMID: 28856604]
[59]
Lv P, Chen Y, Wang D, Wu X, Li QX, Hua R. Synthesis, characterization, and antifungal evaluation of thiolactomycin derivatives. Engineering 2020; 6(5): 560-8.
[http://dx.doi.org/10.1016/j.eng.2019.10.016]
[60]
Jachak SM, Jain R. Current status of target-based antimycobacterial natural products. Antiinfect Agents Med Chem 2006; 5(2): 123-33.
[http://dx.doi.org/10.2174/187152106776359011]
[61]
Diwischek F. Development of synthesis pathways and characterization of cerulenin analogues as inhibitors of the fatty acid biosynthesis of Mycobacterium tuberculosis and of efflux pump resistant Candida albicans. Doctoral Thesis Universität Würzburg, Fakultät für Chemie und Pharmazie 2008.
[62]
Krauss J, Knorr V, Manhardt V, Scheffels S, Bracher F. Synthesis of platensimycin analogues and their antibiotic potency. Arch Pharm (Weinheim) 2008; 341(6): 386-92.
[http://dx.doi.org/10.1002/ardp.200700177] [PMID: 18442030]
[63]
Brown AK, Taylor RC, Bhatt A, Fütterer K, Besra GS. Platensimycin activity against mycobacterial β-ketoacyl-ACP synthases. PLoS One 2009; 4(7): e6306.
[http://dx.doi.org/10.1371/journal.pone.0006306] [PMID: 19609444]
[64]
Jang KP, Kim CH, Na SW, et al. 7-Phenylplatensimycin and 11-methyl-7-phenylplatensimycin: more potent analogs of platensimycin. Bioorg Med Chem Lett 2010; 20(7): 2156-8. [Internet].
[http://dx.doi.org/10.1016/j.bmcl.2010.02.037] [PMID: 20207542]
[65]
Patra M, Gasser G, Wenzel M, Merz K, Bandow JE, Metzler-nolte N. Synthesis and biological evaluation of ferrocene-containing bioorganometallics inspired by the antibiotic platensimycin lead structure. Organomettalics 2010; 29(19): 4312-9.
[http://dx.doi.org/10.1021/om100614c]
[66]
Moustafa GAI, Nojima S, Yamano Y, et al. Potent growth inhibitory activity of (±)-platencin towards multi-drug-resistant and extensively drug-resistant Mycobacterium tuberculosis. MedChemComm 2013; 4(4): 720-3.
[http://dx.doi.org/10.1039/c3md00016h]
[67]
Dong LB, Rudolf JD, Shen B. Antibacterial sulfur-containing platensimycin and platencin congeners from Streptomyces platensis SB12029. Bioorg Med Chem 2016; 24(24): 6348-53.
[http://dx.doi.org/10.1016/j.bmc.2016.04.026] [PMID: 27134119]
[68]
Dong LB, Rudolf JD, Lin L, Ruiz C, Cameron MD, Shen B. In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin. Bioorg Med Chem 2017; 25(6): 1990-6.
[http://dx.doi.org/10.1016/j.bmc.2017.02.028] [PMID: 28237556]

Rights & Permissions Print Cite
Article Metrics
57
1
© 2024 Bentham Science Publishers | Privacy Policy